ATE523788T1 - ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN - Google Patents

ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Info

Publication number
ATE523788T1
ATE523788T1 AT06011829T AT06011829T ATE523788T1 AT E523788 T1 ATE523788 T1 AT E523788T1 AT 06011829 T AT06011829 T AT 06011829T AT 06011829 T AT06011829 T AT 06011829T AT E523788 T1 ATE523788 T1 AT E523788T1
Authority
AT
Austria
Prior art keywords
ratio
alzheimer
diagnosis
determination
secretase
Prior art date
Application number
AT06011829T
Other languages
English (en)
Inventor
Gerd Multhaup
Lisa Muenter
Original Assignee
Fu Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fu Berlin filed Critical Fu Berlin
Application granted granted Critical
Publication of ATE523788T1 publication Critical patent/ATE523788T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AT06011829T 2006-06-08 2006-06-08 ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN ATE523788T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011829A EP1865326B1 (de) 2006-06-08 2006-06-08 Assay zur Diagnose von Alzheimer basierend auf der Bestimmung des Verhältnisses von Sekretase-Aß-Spaltprodukten

Publications (1)

Publication Number Publication Date
ATE523788T1 true ATE523788T1 (de) 2011-09-15

Family

ID=36922150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06011829T ATE523788T1 (de) 2006-06-08 2006-06-08 ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Country Status (6)

Country Link
US (1) US20100221759A1 (de)
EP (2) EP1865326B1 (de)
CN (1) CN101460853A (de)
AT (1) ATE523788T1 (de)
ES (1) ES2373048T3 (de)
WO (1) WO2007140843A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005528887A (ja) * 2002-01-31 2005-09-29 エクスプレッシブ コンストラクツ，インコーポレイテッド 微生物の検出方法
WO2008058760A1 (en) * 2006-11-17 2008-05-22 Friedrich-Alexander-Universität Erlangen-Nürnberg Method of differentially diagnosing dementias
WO2008148098A2 (en) * 2007-05-24 2008-12-04 University Of Rochester Detection of fragments of nectin-1 for the diagnosis of alzheimer's disease
US20100028918A1 (en) * 2008-07-31 2010-02-04 Probiodrug Ag Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases
EP2344881A4 (de) * 2008-09-26 2012-03-07 Univ Melbourne Biomarker für morbus alzheimer
DE102009054057A1 (de) * 2009-11-20 2011-05-26 Charité - Universitätsmedizin Berlin (Charité) Screening-Verfahren für Wirkstoffe für die Prophylaxe und Therapie neurodegenerativer Erkrankungen
EP2511296A1 (de) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
WO2014040042A2 (en) 2012-09-10 2014-03-13 The Johns Hopkins University Diagnostic assay for alzheimer's disease
ES2498465B1 (es) * 2013-02-20 2015-09-17 Universidad Miguel Hernández De Elche Método de diagnóstico y/o pronóstico de la enfermedad de alzheimer
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
AU2015262399B9 (en) * 2014-05-22 2021-07-22 National Center For Geriatrics And Gerontology Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
CN105002172B (zh) * 2015-07-31 2017-07-11 北京泱深生物信息技术有限公司 检测eapp基因表达的试剂在诊治阿尔茨海默病中的应用
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021589A1 (en) * 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
PL205294B1 (pl) * 1998-09-24 2010-03-31 Upjohn Co Izolowany lub oczyszczony polipeptyd, oczyszczony lub izolowany polinukleotyd, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania polipeptydu, sposoby identyfikowania czynnika obniżającego, modulującego lub hamującego aktywność, zastosowanie takiego czynnika, izolowany kwas nukleinowy, obejmujący go wektor i ich zastosowanie, sposoby zmniejszania komórkowego wytwarzania beta amyloidu i zastosowanie antysensownego reagenta
AU2001269127A1 (en) * 2000-07-06 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel app mutation associated with an unusual alzheimer's disease pathology
WO2003001881A2 (en) * 2001-06-26 2003-01-09 New York State Office Of Mental Health Cell-based high-throughput screening methods
WO2003040183A2 (en) * 2001-11-09 2003-05-15 The Genetics Company, Inc Compounds for the diagnosis/prevention/treatment of alzheimer's disease
AU2003248635A1 (en) * 2002-06-05 2003-12-22 Buck Institute Secretases related to alzheimer's dementia
DE602005010241D1 (de) * 2004-05-24 2008-11-20 Univ Muenchen L Maximilians Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis

Also Published As

Publication number Publication date
CN101460853A (zh) 2009-06-17
EP2032990A2 (de) 2009-03-11
WO2007140843A3 (en) 2008-04-24
EP1865326B1 (de) 2011-09-07
EP1865326A1 (de) 2007-12-12
WO2007140843A2 (en) 2007-12-13
US20100221759A1 (en) 2010-09-02
ES2373048T3 (es) 2012-01-30

Similar Documents

Publication Publication Date Title
WO2007140843A3 (en) Assay for the diagnosis of alzheimer's disease based on the determination of the ratio of gamma-secretase abeta cleavage products
MA29282B1 (fr) Procede de diagnostic d'une steatose hepatique au moyen de marqueurs biochimiques
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
SG141418A1 (en) Method for the detection of gene transcripts in blood and uses thereof
WO2008021515A3 (en) Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2007028161A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
ATE511651T1 (de) Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
TW200502400A (en) Nucleic acid detection
WO2006119775A3 (en) Method for diagnosis and treatment, of a mental disease
EP1572225A4 (de) Thrombospondinfragmente und deren verwendung bei klinischen krebs-tests und der erzeugung von antikörpern und sonstigen bindungsmitteln
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
EP2062983A3 (de) Primer und Sonden zum Nachweis genitaler HPV-Genotypen
FR2936060B1 (fr) Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.
ATE406579T1 (de) Verfahren zur diagnose von tumoren
DE602006015221D1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties